British biopharmaceutical company Wren Therapeutics has raised 18 million pounds ($23.2 million) in a Series A financing round.
The new capital will enable Wren Therapeutics to advance pipeline for protein misfolding diseases.
The Series A round was led by U.S. fund management company The Baupost Group.
The round also had participation from U.S. digital health investment firm LifeForce Capital and several high net worth individual backers.